TOP > 外国特許検索 > RECOMBINANT EXPRESSION VECTOR AND LIPID MEMBRANE STRUCTURE HAVING SAID VECTOR ENCAPSULATED THEREIN

RECOMBINANT EXPRESSION VECTOR AND LIPID MEMBRANE STRUCTURE HAVING SAID VECTOR ENCAPSULATED THEREIN

外国特許コード F170009107
整理番号 (S2016-0168-N0)
掲載日 2017年6月15日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP085098
国際公開番号 WO 2017090763
国際出願日 平成28年11月28日(2016.11.28)
国際公開日 平成29年6月1日(2017.6.1)
優先権データ
  • 特願2015-230498 (2015.11.26) JP
発明の名称 (英語) RECOMBINANT EXPRESSION VECTOR AND LIPID MEMBRANE STRUCTURE HAVING SAID VECTOR ENCAPSULATED THEREIN
発明の概要(英語) [Problem] To provide a novel expression vector capable of effectively expressing a target protein in mitochondria and suppressing undesirable expression of the target protein in cell organelles other than mitochondria.
[Solution] The present invention provides a recombinant expression vector for expressing a target protein in mitochondria of animal cells, and a lipid membrane structure having the vector encapsulated therein, wherein the recombinant expression vector has a promoter sequence exhibiting a transcription activity in the nuclei of animal cells, and has, under the control of the promoter sequence, a coding region which codes a target protein and includes one or more TGAs as codons corresponding to tryptophan. The recombinant expression vector according to the present invention can more efficiently and selectively express a target protein in mitochondria, and can be used as a more safe and effective drug for treating mitochondrial diseases.
従来技術、競合技術の概要(英語) BACKGROUND ART
1 Is one of the mitochondria of organelles in a cell, cell nucleus has independent genomic DNA. Between a mutation in the genomic DNA of a variety of diseases (brain fibromyalgia, neurodegenerative disease, cancer, such as diabetes) has been reported a large number of related, these are generically referred to as a mitochondrial disease.
As a treatment method of mitochondria, mitochondrial protein in the expected therapeutic effect can be expressed in gene therapy and for the purpose. As a method of realizing the method according to claim, expressed in a cell nucleus to cause the transfer of the protein of interest using a method in the mitochondria, and mitochondrial directly within the target protein can be expressed foreign gene expression system has been proposed a method of using.
The target protein is expressed in the cell nucleus to be transported to the mitochondria in connection with the method, a wide variety of expression vectors have been developed. Many of, the genome of the cell nucleus encoded mitochondrial protein has, mitochondrial migration signal peptide that utilizes (mitochondrial targeting signal peptide, MTS). Specifically, the target protein upstream of the MTS (MTS added protein) an expression vector encoding were delivered into the nucleus, additional MTS protein expressed in the cytoplasm, although it is delivered to the mitochondria.
In this method is a type of target protein may be useful, gene therapy is expected to be used is, mitochondrial protein encoded by the mitochondrial genome DNA (mitochondrial endogenous proteins) has a problem in the applicability to the display. Is in the cytoplasm and mitochondria of an endogenous protein is insoluble in many for, expressed in the cytoplasm and mitochondria of agglomeration of the endogenous protein, into the mitochondria transition becomes insufficient in some cases.
Patent Document 1 is, the water-soluble increased mitochondrial specific MTS MTS or added protein from an endogenous protein and encoding using an expression vector, aggregation in the cytoplasm of the protein of interest is a method has been disclosed. However, the endogenous protein is mitochondria, subcellular organelles other than mitochondria and therefore it is cytotoxic to the, method described in Patent Document 1 can be used limit the range of the protein of interest.
In addition, the method comprises using MTS added protein, intracellular transport of an endogenous protein in the mitochondria of the original interference or by competing with the cell and possibly damage the lethal, concern remains as a tool for gene therapy.
On the other hand, mitochondrial directly within the target protein can be expressed in the employment of a foreign gene expression system, a necessary and sufficient amount in the first mitochondrial transcript expression of a protein of interest is required. So as to be adapted for such purpose, a promoter derived from a gene present in the mitochondrial genome DNA, for example selected HSP (heavy strand promoter), which encodes a target protein under its control is placed some DNA designed expression vector. The expression vector may, in the mitochondrial genome DNA triplet devised such as using a high frequency of use is also added. However, to date, the expression level of the expression vector are necessary and sufficient for the treatment of other region has not yet been attained.
For example, the non-patent document 1, the inside of the artificial viral vector MTS HSP is added under the control of the transcriptional induction in mitochondria DNA are sealed, directly to the viral vector is introduced into the mitochondrial target protein are to be expressed be method have been proposed. This method is, introduced from the viral vector of the expression of the target protein level is relatively high on the other hand has the advantage that, due to a viral vector in addition to entailing safety problems, as expected the protein of interest expressed in the mitochondria of the verification or not completely spoken.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • HOKKAIDO UNIVERSITY
  • 発明者(英語)
  • HARASHIMA Hideyoshi
  • YAMADA Yuma
  • ISHIKAWA Takuya
  • AKITA Hidetaka
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください

PAGE TOP

close
close
close
close
close
close